Craft
NxStage Medical

NxStage Medical

Revenue

$393.9 M

FY, 2017

NxStage Medical Summary

Company summary

Overview
NxStage Medical, Inc. is a medical technology company that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. Its primary product includes the NxStage System One (the System One). NxStage operates in two segments: System One and In-Center. The Company markets the System One to hospitals for treatment of acute kidney failure and fluid overload. In addition to the System One, NxStage sells a line of extracorporeal disposable products for use primarily for in-center dialysis treatments for patients with end-stage renal disease (ESRD). These products, which consist of Medisystems, include hemodialysis blood tubing sets, A.V. fistula needles and apheresis needles. The Company's blood tubing set products include the ReadySet High Performance Blood Tubing set (ReadySet), and the Streamline Airless Blood Tubing set (Streamline).
Type
Subsidiary
Status
Active
Founded
1998
HQ
Lawrence, MA, US | view all locations
Website
http://www.nxstage.com/
Cybersecurity rating
Sectors

Key people

  • Jeff Burbank

    Jeff Burbank, CEO

    • Matthew W. Towse

      Matthew W. Towse, CFO

      • Joseph E. Turk

        Joseph E. Turk, President

        • Lisa Curtis

          Lisa Curtis, SVP, International

          LocationsView all

          36 locations detected

          • Lawrence, MA HQ

            United States

            350 Merrimack St

          • Atlanta, GA

            United States

            Atlanta, GA, USA

          • Baton Rouge, LA

            United States

            Baton Rouge, LA, USA

          • Birmingham, AL

            United States

            Birmingham, AL, USA

          • Brunswick, OH

            United States

            1418 Town Center Blvd

          • Buffalo, NY

            United States

            Buffalo, NY, USA

          and 30 others

          NxStage Medical Financials

          Summary financials

          Revenue (Q3, 2018)
          $108.1M
          Gross profit (Q3, 2018)
          $46.5M
          Net income (Q3, 2018)
          $881.0K
          Cash (Q3, 2018)
          $81.9M
          EBIT (Q3, 2018)
          $1.3M

          Footer menu